Relationship between 5-fluorouracil disposition, toxicity and dihydropyrimidine dehydrogenase activity in cancer patients

Annals of Oncology

Volumn 12, Issue 9, 2001, Pages 1301-1306

  Di Paolo, A ^a   Danesi, R ^a   Falcone, A ^b   Cionini, L ^a   Vannozzi, F ^a   Masi, G ^b   Allegrini, G ^b   Mini, E ^a   Bocci, G ^a   Conte, P F ^b   Del Tacca, M ^a  

^a UNIVERSITY OF PISA   (Italy)

^b Division of Medical Oncology   (Italy)

Author keywords

5 fluorouracil; DPD; Metabolism; Pharmacokinetics; Toxicity

Indexed keywords

DIHYDROFLUOROURACIL; DIHYDROPYRIMIDINE DEHYDROGENASE; DRUG METABOLITE; FLUOROURACIL; FOLINIC ACID;

ADJUVANT CHEMOTHERAPY; ADULT; ADVERSE DRUG REACTION; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG METABOLISM; DRUG TOLERABILITY; DRUG TOXICITY; ENZYME ACTIVITY; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL TOXICITY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONONUCLEAR CELL; MUCOSA INFLAMMATION; NAUSEA; PREDICTION; PRIORITY JOURNAL; STOMATITIS; VOMITING; WORLD HEALTH ORGANIZATION;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; CHEMOTHERAPY, ADJUVANT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OXIDOREDUCTASES;

EID: 0034782963     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1012294617392     Document Type: Article

References (18)

1. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency
2. Life-threatening toxicity in a dihydropyrimidine dehydrogenase-deficient patient after treatment with topical 5-fluorouracil
3. Dihydropyrimidine dehydrogenase activity: Prognostic partner of 5-fluorouracil?
4. Distribution and inhibition of dihydrouracil dehydrogenase activities in human tissues using 5-fluorouracil as a substrate
5. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy
6. Link between dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells and liver
7. Relationship between dihydropyrimidine dehydrogenase activity and plasma 5-fluorouracil levels with evidence for circadian variation of enzyme activity and plasma drug levels in cancer patients receiving continuous infusion
8. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients
9. Depressed hepatic dihydropyrimidine dehydrogenase activity and fluorouracil-related toxicities
10. Individualizing therapy with 5-fluorouracil related to dihydropyrimidine dehydrogenase: Theory and limits
11. Population study of dihydropyrimidine dehydrogenase in cancer patients
12. Familial pyrimidinemia and pyrimidinuria associated with severe fluorouracil toxicity
13. Dihydropyrimidine dehydrogenase deficiency and fluorouracil-related toxicity
14. Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer
15. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: A potential interest for predicting 5-FU optimal 5-FU dosage
16. cDNA cloning and chromosome mapping of human dihydropyrimidine dehydrogenase, an enzyme associated with 5-fluorouracil toxicity and congenital thymine uraciluria
17. Inter- and intraindividual variation in dihydropyrimidine dehydrogenase activity in peripheral blood mononuclear cells
18. Profound variation in dihydropyrimidine dehydrogenase activity in human blood cells: Major implications for the detection of partly deficient patients